Paper Details

  1. Home
  2. Paper Details

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Author: , AtkinsJames N, BeversTherese B, CecchiniReena S, CostantinoJoseph P, CroninWalter M, FehrenbacherLouis, FordLeslie G, GanzPatricia A, JamesJoan, JordanV Craig, LippmanScott M, MargoleseRichard G, McCaskill-StevensWorta, PajonEduardo R, ReisSteven E, RobidouxAndré, RunowiczCarolyn D, VogelVictor G, WadeJames L, WickerhamD Lawrence, WolmarkNorman

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Raloxifene and tamoxifen are both effective in reducing the risk of invasive breast cancer in postmenopausal women, but have different side effect profiles. In a large randomized trial of nearly 20,000 women, both drugs demonstrated similar reductions in invasive breast cancer risk. Raloxifene was associated with a lower risk of thromboembolic events and cataracts, while tamoxifen had a non-statistically significant higher risk of noninvasive breast cancer.
Paper Details　
Original Abstract of the Article :
CONTEXT: Tamoxifen is approved for the reduction of breast cancer risk, and raloxifene has demonstrated a reduced risk of breast cancer in trials of older women with osteoporosis. OBJECTIVE: To compare the relative effects and safety of raloxifene and tamoxifen on the risk of developing invasive br...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1001/jama.295.23.joc60074

データ提供：米国国立医学図書館（NLM）

Tamoxifen vs. Raloxifene: A Desert of Choice for Breast Cancer Prevention

This study explores the relative effectiveness and safety of two drugs, tamoxifen and raloxifene, in reducing the risk of breast cancer in postmenopausal women. It's like navigating a vast and complex desert, where each path offers its own unique benefits and risks. The researchers compared the effects of these drugs on breast cancer risk, as well as other health outcomes, seeking to identify the most appropriate option for individual patients.

Comparing Tamoxifen and Raloxifene for Breast Cancer Prevention

The study found that both tamoxifen and raloxifene are effective in reducing the risk of invasive breast cancer, with similar overall effectiveness. This research is like uncovering two different oases in the desert of breast cancer prevention, each offering its own unique qualities. The study also highlighted that raloxifene has a lower risk of thromboembolic events and cataracts, but a slightly higher risk of noninvasive breast cancer compared to tamoxifen. This information provides valuable insights that can help guide individual decisions about breast cancer prevention strategies.

Making Informed Choices for Breast Cancer Prevention

This research emphasizes the importance of personalized medicine and the need to carefully consider the potential benefits and risks of different medications for breast cancer prevention. It's like choosing the right path through a desert, where each route presents its own unique challenges and rewards. The study's findings can help women make informed choices about their breast cancer prevention strategies, working in close collaboration with their healthcare providers.

Dr.Camel's Conclusion

This research is a reminder that the desert of breast cancer prevention is complex and nuanced, with no single solution fitting all. It's a journey that requires careful planning, informed decision-making, and ongoing communication with healthcare professionals. The study's findings provide valuable insights that can help women navigate this journey, taking the most appropriate path towards a healthier future.

Date :
  1. Date Completed 2006-06-26
  2. Date Revised 2022-04-10
Further Info :

Pubmed ID

16754727

DOI: Digital Object Identifier

10.1001/jama.295.23.joc60074

Related Literature

Article Analysis
・Effects of raloxifene
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.